regulatory authorities have a different view [Dissolution / BCS / IVIVC]

posted by Dr_Dan  – Germany, 2015-09-15 10:53 (3505 d 07:45 ago) – Posting: # 15398
Views: 10,751

Dear Mauricio
in contrast to stable drugs the curve of the dissolution profile of a capecetabine formulation will not asymptotically approximate the 100% but decline after reaching a maximum which can not be 100%. It is reasonable to assume that everything is all right as Long as you can show similarity of the disso profile of your test formulation with the reference formulation, however, you have no proof. IMHO this is the reason why regulatory authorities have a different view (see this recent post of Helmut). In disso testing you regard two processes, disintegration and dissolution. In case of capecitabine there is a third process, degradation. It could be assumed that this third processes superimposes the first two processes and that therefore differences in formulation can not be detected.
I hope this helps.
Kind regards
Dr_Dan

Kind regards and have a nice day
Dr_Dan

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,676 registered users;
35 visitors (0 registered, 35 guests [including 7 identified bots]).
Forum time: 18:39 CEST (Europe/Vienna)

It is true that many scientists are not philosophically minded
and have hitherto shown much skill and ingenuity
but little wisdom.    Max Born

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5